Clinical Trial Update: A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Temferon, a hematopoietic stem cell gene therapy, for metastatic renal cell carcinoma (clear cell RCC) has been terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Temferon (temferon)

Snippet

Sponsor: Genenta Science | Conditions: Clear Cell RCC | Phase 1, Phase 2 | Status: TERMINATED